Member Info for Moneymunch

Yep, massive UPside potential, and every chance of an early lucrative licensing deal , given that Genflow signed an MTA in April 2025 with a ophthalmology partner .Gl ;-)

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company’s new development program targeting eye health.

The initiative focuses on using a patented variant of the SIRT6 gene in combination with mRNA therapies. Leire explained that gene therapy is particularly well-suited for the eye due to its closed compartment, reducing the risks of off-target effects and immune responses.

The company is developing two parallel therapeutic applications: one for the posterior part of the eye to address glaucoma, and another for the anterior part, targeting corneal endothelial cell preservation in transplant procedures.

“We expect by a simple in vitro… to add our SIRT6 to these preservation media and help to increase the rate of positive transplantation of cornea,” said Leire, highlighting the opportunity to improve corneal transplant success rates without clinical trials.

Glaucoma therapy, on the other hand, involves a more complex delivery using mRNA injections, aiming to both reduce intraocular pressure and regenerate damaged ganglion cells. The company has already signed an MTA with an ophthalmology partner to initiate early development, starting with corneal preservation and expanding into glaucoma.

Genflow sees this as a fast-track opportunity to build an ophthalmology franchise with meaningful market potential and low incremental cost.

Genflow Bioscinces eyes glaucoma Cure with SIRT6 bregakthrough | LSE:GENF, OTCQB:GENFF https://share.google/gkRhWX91ds8XhgAX3

Lol, I'm find and dandy Porter and have been patiently ( through gritted teeth ) awaiting full recovery in our fortunes as multiple positive newsflow arrives. Game changing news on the Dog Trial could drop at anytime, although Eric did highlight the 7th July in the 20/2/25 RNS and so maybe news tomorrow judging by the increased trading volume. Gl :-)

· Result: The application met all requirements of the European Patent Convention (EPC).

· Next Steps: Genflow is preparing its intention to advance the application required by 7 July 2025

htTps://www.lse.co.uk/rns/GENF/advancements-in-sirt6-variant-patent-application-d6nhla1fyd3xy80.html

My bargain basement 69.4k top up is showing as a sell. Gla, game changing news at anytime!!! :-)

Interesting development, not too sure a set back for Genflow or the opposite, but something Israel wasn't expecting as they continue their genocide in Gaza.

The SirtLab address is Pinhas Sapir 3, Weizmann Park, Ness Ziona, Israel.

SIRTLab is a biotechnology company focused on developing therapeutics that boost levels of the protein SIRT6, which is implicated in longevity and healthy aging. They are particularly interested in targeting severe liver diseases and diseases of aging by restoring SIRT6 expression. Their approach involves using mRNA-LNP technology to deliver SIRT6 to the liver, with the goal of achieving systemic effects.

Key aspects of SIRTLab's work:

SIRT6 Focus:

SIRTLab is centered around the protein SIRT6, which is a sirtuin protein known for its role in regulating cellular processes related to aging, such as glucose metabolism, DNA repair, and inflammation.

Therapeutic Approach:

The company's primary goal is to develop therapeutics that increase SIRT6 levels in the body, with the aim of addressing age-related diseases and promoting healthy aging.

mRNA-LNP Delivery:

SIRTLab utilizes a patented mRNA-LNP (lipid nanoparticle) technology to deliver SIRT6 specifically to the liver, enabling systemic effects through liver-organ communication.

Research Background:

The company's work is rooted in the research of Haim Cohen, a professor at Bar-Ilan University and a leading expert on SIRT6.

Clinical Trials:

SIRTLab is planning to move into clinical trials, with the first stage potentially involving safety studies in monkeys and then progressing to human trials.

Longevity Focus:

SIRTLab explicitly positions itself as a longevity-focused company, aiming to extend healthy lifespan by targeting SIRT6.

REHOVOT, Israel (AP) — For years, Israel has targeted Iranian nuclear scientists, hoping to choke progress on Iran’s nuclear program by striking at the brains behind it.

Now, with Iran and Israel in an open-ended direct conflict, scientists in Israel have found themselves in the crosshairs after an Iranian missile struck a premier research institute known for its work in life sciences and physics, among other fields.

While no one was killed in the strike on the Weizmann Institute of Science early Sunday, it caused heavy damage to multiple labs on campus, snuffing out years of scientific research and sending a chilling message to Israeli scientists that they and their expertise are now targets in the escalating conflict with Iran.

Damage to the Weizmann Institute of Science from an Iranian missile strike in Rehovot, Thursday, June 19, 2025. (AP Photo/Maya Alleruzzo)

Read More

“It’s a moral victory” for Iran, said Oren Schuldiner, a professor in the department of molecular cell biology and the department of molecular neuroscience whose lab was obliterated in the strike. “They managed to harm the crown jewel of science in Israel.”

htTps://apnews.com/article/israel-iran-scientists-weizmann-strike-0

RNS Number : 7719M

Genflow Biosciences PLC

17 June 2025

17 June 2025

Genflow Biosciences Plc

Genflow Biosciences Provides Half Year Corporate Update on SIRT6 Programs, IP Progress and Strategic Partnerships

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to provide an update on the continued advancement of its core programs focused on the SIRT6-centenarian gene and its potential to slow aging and delay the onset of age-related diseases.

Since the start of the year, the Company has made meaningful progress across its research and development initiatives. These advancements have been supported by a strengthened leadership network of world-class academic collaborators and laboratories. Combined with the continued support of international institutional investors and previously awarded government grants, this ecosystem has played a vital role in accelerating Genflow's scientific and clinical development.

As part of its strategic execution, Genflow has signed a Master Service Agreement (MSA) with CER Groupe, a trusted long-term partner and leading Belgian research center specializing in integrated bioproduction and pre-clinical services. CER operates in a fully regulated ISO and GxP-compliant environment and will provide a robust R&D framework to support the advancement of Genflow's pre-IND gene therapy programs.

In parallel, the Company continues to expand its global intellectual property portfolio. In February, Genflow's exclusively out-licensed European Patent Office (EPO) application titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases" advanced through the Supplementary European Search Report without objections, allowing it to proceed to the national phase-a key step toward securing protections across major European markets.

Similarly, the Japanese Patent Office has progressed the same SIRT6-related application (Application No. JP 2024515284) to the national examination phase, marking another important milestone in establishing global IP coverage for Genflow's innovative gene therapy technology.

Originally filed on 13 May 2022, the patent is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusive worldwide license to this intellectual property.

To support the intellectual property costs associated with entering into the national phase in the U.S., Canada, Europe, Japan, Australia, China, Genflow has applied for a PATEX-2 grant in connection with its patent application PCT/EP2023/084840, titled "SIRT6 Variants for NASH," filed on December 8, 2023. This patent is fully owned by Genflow Biosciences.

Below is a status update on each of our programs, reflecting significant progress at the mid-year point:

MASH

IP rights under the agreement. Our MASH program receives support through a research grant awarded by the regional government of Wallonia - Belgium Service Public de Wallonie.

Werner Syndrome (GF-1003): We have developed a proprietary liver organoid model derived from human cells of patients with Werner syndrome. This innovative system allows us to test our drug candidate, GF-1003, directly in a disease-relevant human tissue model. The approach offers several advantages: it reduces the need for animal testing and provides deeper insight into the efficacy and safety of GF-1003 in a synthetic organ created from the cells of three Werner syndrome patients. As a result, this model significantly enhances the predictive value of our preclinical data for the potential success of future clinical trials in Werner patients.

The use of more sophisticated organoid models reflects Genflow's strong commitment to minimizing animal suffering wherever possible. While this approach involves higher costs and longer development timelines, it aligns with our core values and ethical commitment to respecting animal welfare. By prioritizing human-relevant, non-animal models, Genflow demonstrates that scientific progress and compassion can go hand in hand.

Our Werner program receives support through a research grant awarded by the regional government of Wallonia.

Dog Aging (GF-1004): In March, we commenced a proof-of-concept clinical trial to evaluate the safety and efficacy of its proprietary SIRT6-centenarian gene therapy targeting age-related decline in dogs. The Company is treating the dogs for 6 months and assess the safety and efficacy of our therapy for the following 6 months. This is a randomized, controlled trial with 28 dogs aged 10+ years, conducted with the renowned CRO, Syngene. Genflow will compare recipient dogs of intravenous injections of proprietary SIRT6 gene therapy versus untreated control group. Endpoints will include biological age estimation (via GRIM methylation clock), muscle strength, muscle mass, mitochondrial function, coat quality and overall health indicators.

Sarcopenia (GF-1005): Our sarcopenia program, aimed at combating age-related muscle loss, continues to progress positively with GF-1005-myoblast progenitor cells engineered to express the centenarian variant of SIRT6 (centSIRT6). This project is being carried out in collaboration with our partners at Université libre de Bruxelles (ULB) and Revatis.

Building on this foundation, Genflow has identified three additional sirtuin genes that may act synergistically with centSIRT6. This has led to the development of four drug candidates: GF-10051, which expresses centSIRT6 alone, and GF-10052, GF-10053, and GF-10054, each co-expressing centSIRT6 with one of the three potentially synergistic sirtuin genes. We have successfully achieved stable dual gene expression-a technically challenging feat due to the large size of the combined genetic constructs. T

IP rights under the agreement. Our MASH program receives support through a research grant awarded by the regional government of Wallonia - Belgium Service Public de Wallonie.

Werner Syndrome (GF-1003): We have developed a proprietary liver organoid model derived from human cells of patients with Werner syndrome. This innovative system allows us to test our drug candidate, GF-1003, directly in a disease-relevant human tissue model. The approach offers several advantages: it reduces the need for animal testing and provides deeper insight into the efficacy and safety of GF-1003 in a synthetic organ created from the cells of three Werner syndrome patients. As a result, this model significantly enhances the predictive value of our preclinical data for the potential success of future clinical trials in Werner patients.

The use of more sophisticated organoid models reflects Genflow's strong commitment to minimizing animal suffering wherever possible. While this approach involves higher costs and longer development timelines, it aligns with our core values and ethical commitment to respecting animal welfare. By prioritizing human-relevant, non-animal models, Genflow demonstrates that scientific progress and compassion can go hand in hand.

Our Werner program receives support through a research grant awarded by the regional government of Wallonia.

Dog Aging (GF-1004): In March, we commenced a proof-of-concept clinical trial to evaluate the safety and efficacy of its proprietary SIRT6-centenarian gene therapy targeting age-related decline in dogs. The Company is treating the dogs for 6 months and assess the safety and efficacy of our therapy for the following 6 months. This is a randomized, controlled trial with 28 dogs aged 10+ years, conducted with the renowned CRO, Syngene. Genflow will compare recipient dogs of intravenous injections of proprietary SIRT6 gene therapy versus untreated control group. Endpoints will include biological age estimation (via GRIM methylation clock), muscle strength, muscle mass, mitochondrial function, coat quality and overall health indicators.

Sarcopenia (GF-1005): Our sarcopenia program, aimed at combating age-related muscle loss, continues to progress positively with GF-1005-myoblast progenitor cells engineered to express the centenarian variant of SIRT6 (centSIRT6). This project is being carried out in collaboration with our partners at Université libre de Bruxelles (ULB) and Revatis.

Building on this foundation, Genflow has identified three additional sirtuin genes that may act synergistically with centSIRT6. This has led to the development of four drug candidates: GF-10051, which expresses centSIRT6 alone, and GF-10052, GF-10053, and GF-10054, each co-expressing centSIRT6 with one of the three potentially synergistic sirtuin genes. We have successfully achieved stable dual gene expression-a technically challenging feat due to the large size of the combined genetic const

Most certainly, share accumulation as cheap shares are mopped UP from impatient pi's ....Multiple material newsflow in the pipeline. Gl :-)

Now we've had official confirmation of the new enlarged number of shares in issue, will hopefully prompt a TR1 or two for disclosure and transparency. Watch this space!!! In the meantime, fully expect a run of continued material newflow from now on in, across the pipeline, and of course Proof of Concept on the Dog Trial could drop at anytime. Gla Holders, and fingers crossed for a stellar period ahead and plenty of UPside momentum. :-)

The figure of 453,547,942 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Another brick in the wall Rooster, as we await potential game changing news on the Dog Trial, as well as progress on the rest of the pipeline, and the tie up with CER will no doubt accelerate Genflow's R&D, including Orphan Drug Status for Werner Syndrome. Poolbeg Pharma were up 70% plus yesterday on confirmation of FDA approval for Orphan Drug Status for their drug target, and so something similar for Genflow in the pipeline. Gl ;')

CER Groupe is a Belgian Collective Research Centre supporting human and veterinary health by providing products, research and services to companies active in the biotech, medtech, pharma, food and agrotech fields.

Our integrated discovery and development platform is focused on non-clinical development, biomanufacturing (antibodies, proteins and viral vectors) and food & feed testing services, all supported by high-tech analytical platforms (including immunomonitoring, proteomic, metabolomic, in vitro & in vivo imaging).

We are mainly active in immunology, oncology, cell & gene therapy, infectiology and medical device sectors, with a strong track record of successful collaborations. Thanks to our 15000 sqm of operational facilities, our 200+ collaborators and our 45+ years of expertise, we are committed to offer flexible, tailored and integrated solutions, from hit discovery to lead toxicity evaluation and routine services, at the highest quality standards (ISO9001, ISO17025 and GLP).

Visit our website www.cergroupe.be and follow us on LinkedIn www.linkedin.com/company/cer-groupe to get the latest news

RNS Number : 2547K

Genflow Biosciences PLC

28 May 2025

28 May 2025

Genflow Biosciences Plc

Genflow Biosciences and CER Sign Master Service Agreement to Strengthen Long-Term R&D Collaboration

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to announce the signing of a Master Service Agreement (MSA) with CER Groupe (CER), a long-standing partner of the Company.

CER is a private Belgian research center offering integrated bioproduction and pre-clinical services within a regulated ISO and GxP-compliant environment. The MSA formalizes the working relationship between Genflow and CER, providing a robust R&D framework to accelerate Genflow's pre-IND gene therapy programs.

Under the terms of the MSA, Genflow and CER will:

· Develop, produce and characterize Genflow's gene therapy candidates;

· Implement a collaborative project management system to drive efficient execution and timely deliverables supporting Genflow's goals with standardized templates for Task Orders and technical services; and

· Combine scientific expertise derisks, innovate and ensure relevant scientific outcomes.

Said Dr. Eric Leire, CEO of Genflow: "Our partnership with CER has been instrumental in supporting our R&D efforts to date. Formalizing this collaboration through the MSA will enable greater operational alignment and strategic agility as we continue to accelerate our pipeline."

Proof of Concept from the ongoing Dog Trial and potential confirmation of a commercial licensing deal with Genflow's Vet Partner could drop at anytime. Gla holders ;-)

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,942 followers

18h

Gene Therapy – The Future of Canine #Longevity?

Cutting edge research suggests #gene therapy could slow down the #aging process in dogs by enhancing #DNA repair, reducing inflammation, and improving metabolic function.

At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we’re pioneering Centenarian #SIRT6-based gene therapies to help dogs live longer, healthier lives.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,937 followers

4d

🧬 Longevity biotech is breaking out of the lab!

According to Forbes and Grand View Research, Inc, the anti-aging industry surpassed $50B in value in 2024, with tailwinds from #aging populations, #biotech innovation, and increasing public sector support.

The field is now rich with opportunity - from #gene editing and AI-powered drug discovery to microbiome therapies and #regenerative medicine.

Author Abdo Riani singles out #SIRT6 as a particularly promising candidate in gene editing therapy. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is advancing research on the #centenarian variant of SIRT6, exploring its potential to combat #aging and age-related diseases like #glaucoma.

Read more: https://loom.ly/0tnIWM0

The 62.5m share allotment/ subscription for £500k has just popped up delayed from yesterday, and so we should have a TR1 early next week with details of the purchaser, a US based Longevity Fund, and so confirmation could be highly significant and a clear vote of confidence along with the high profile Saudis 4.45% and the Aberdeen Group's 2.6%. Get ready for take off from a clear runway. More good news at anytime, and Proof of Concept on the Dog Trial, which could lead to a commercial licencing deal with their Vet Partner could be close. Gla holders....Exciting times!!! ;-)

Can't be much left Porter follow the Saudi TR1 and Aberdeen Group's 2.6% and so looking forward to some overdue UPside in the coming days. Positive Proof of Concept will see this fly. Gl :-)

Dr. Eric Leire, CEO of Genflow commented: "This positive outcome represents a significant step forward in securing broad intellectual property protection for our innovative work on SIRT6 variants. This milestone strengthens our position in SIRT6-based therapeutics and accelerates our mission to develop effective treatments for age-related diseases."

Japan is part of strengthening Genflow's global position as a leader in longevity gene therapy, and full European approal is fast approaching. In the meantime Genflow has an addittional £935k cash in the bank from the recent equity share investment and subscription to accelererate their Dog Trial, with results expected year end, although Eric did state that Proof of Concept, which would take 6 months, could be enough to secure a commercial licensing deal with their Vet Partner. Proof of Concept began possibly early as January this year, and so potential game changing news at anytime. Plenty more material news expected from the rest of the pipeline, including the first tranche or two from the outstanding 4.7m euro non-dilutie approved grants. Genflow are all set for a stellar run in the coming days and weeks as more good news arrives. Gla holders.....On and UP!!! ;-)

20 February 2025

Genflow Biosciences Advances SIRT6 Variant Patent Application Following Positive Search Report from European Patent Office

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce today that its exclusive, out-licensed patent application for "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases" has successfully progressed through the Supplementary European Search Report without further questions from the European Patent Office (EPO).

The European patent application (EP 22 808 414.1), originally filed on May 13, 2022, by the University of Rochester, The Trustees of Columbia University in the City of New York, and the Albert Einstein College of Medicine, marks a significant step in securing protection for SIRT6 variants, a promising innovation in age-related disease therapeutics. The SIRT6 gene/protein, is known for its critical role in DNA repair, metabolism, and longevity.

Following the EPO's assessment, no further questions were raised, allowing the application to progress to the national phase of the patent process, a critical stage in securing market-specific protections across Europe.

Key Details:

· Application Title: Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases

· Applicants: University of Rochester; The Trustees of Columbia University in the City of New York; Albert Einstein College of Medicine

· Patent Application Number: EP 22 808 414.1

· Filing Date: 13 May 2022

· Result: The application met all requirements of the European Patent Convention (EPC).

· Next Steps: Genflow is preparing its intention to advance the application required by 7 July 2025.

Genflow remains focused on advancing its longevity-focused therapeutic pipeline and will continue to update stakeholders as the patent application progresses.

Dr. Eric Leire, CEO of Genflow commented: "This positive outcome represent

RNS Number : 7021I

Genflow Biosciences PLC

15 May 2025

15 May 2025

Genflow Biosciences plc

Genflow Biosciences Announces Progress of Key SIRT6 Patent Application in Japan

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, announces that the Japanese Patent Office has advanced its SIRT6-related patent application (Application No. JP 2024515284) to the national examination phase.

The application, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was originally filed on 13 May 2022 and is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusive license to this intellectual property.

The invention covers novel SIRT6 gene variants that play a central role in genomic stability, metabolic regulation, and healthy aging. These variants underpin Genflow's core therapeutic platform and represent a key part of its pipeline targeting age-related diseases.

The progression to national examination in Japan marks an important step in Genflow's strategy to establish broad international patent protection. Japan, with one of the world's most rapidly aging populations, is a priority market for longevity-related innovation.

Dr. Eric Leire, CEO of Genflow Biosciences, commented: "We are pleased to see continued momentum in the protection of our SIRT6 intellectual property. Japan represents a strategically important jurisdiction for Genflow, and advancing this patent application strengthens our global positioning as a leader in longevity gene therapy."

Genflow continues to progress its preclinical and clinical programs targeting age-related pathologies using the SIRT6 gene variants.